pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Novo Nordisk Inc · news · pharmadog
← back to Novo Nordisk Inc
News mentioning Novo Nordisk Inc
323
stories
1d
AI drugmaker Isomorphic restocks with $5B fundraise
biopharma dive
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
1d
Why 2027 could be ‘Europe’s year to shine’: Panelists debate biotech funding at Fierce’s London event
fiercebiotech
2d
STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
stat
2d
Novo’s CagriSema drives more than 20% weight loss at lower doses
biospace
2d
Their loss, our gain? Canada makes its case to Europe amid U.S. instability
biospace
5d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
6d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
9d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
9d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
9d
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
stat
9d
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
fiercebiotech
9d
#AHA26: Lilly gets another sleep apnea win, this time with obesity pill
endpoints
9d
Novo’s troubled cardio drug could find niche in less sick patients
biospace
10d
STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
stat
11d
STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
stat
12d
Agios axes 100-plus R&D roles while awaiting FDA decision
biospace
12d
This week in charts: 3 drug launches Wall Street is watching
biopharma dive
13d
The top 12 companies hiring in biopharma now
biospace
14d
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
biopharma dive
14d
STAT+: Ultragenyx cuts staff after another study fails
stat
14d
With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
biospace
14d
Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
biospace
14d
Novo won't launch CagriSema in Europe for 'a couple of years,' CFO says
endpoints
16d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
19d
After Be Bio shutdown, its CEO heads to Orbis; Enanta's longtime chief Jay Luly to retire
endpoints
21d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
21d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
21d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
21d
5 new drug launches that defied industry expectations
biospace
← prev
page 1 of 11
next →